TY - JOUR
T1 - Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated Juvenile Nasopharyngeal Angiofibromas (JNA)
AU - Ponti, Giovanni
AU - Losi, Lorena
AU - Pellacani, Giovanni
AU - Rossi, Giovanni Battista
AU - Presutti, Livio
AU - Mattioli, Francesco
AU - Villari, Domenico
AU - Wannesson, Luciano
AU - Ciufelli, Matteo Alicandri
AU - Izzo, Paola
AU - De Rosa, Marina
AU - Marone, Pietro
AU - Seidenari, Stefania
PY - 2008/3
Y1 - 2008/3
N2 - Juvenile nasopharyngeal angiofibroma (JNA) is a rare, invasive, and locally destructive tumor of the nasopharynx. The Wnt pathway, angiogenetic and hormonal factors are involved in the pathophysiology of JNA; it can result in an extracolonic manifestation of familial adenomatous polyposis (FAP) or in a sporadic tumor. All patients who underwent resection of JNA between 1991 and 2006 at the University of Modena and Reggio Emilia were studied to identify immunohistochemical markers of associated FAP syndrome. Paraffin-embedded JNA samples were analyzed immunohistochemically for the expression of adenomatous polyposis coli (APC), β-catenin, E-cadherin, androgen receptor, and vascular endothelial growth factors receptor (VEGFR2). In one out of the 4 (25%) young patients affected by JNA the diagnosis of FAP syndrome linked to APC mutation was made. All of the sporadic and familial JNA tumors showed nuclear staining of β-catenin, whereas altered APC expression was seen only in FAP-associated JNA. All cases were stained with VEGFR2. A combined clinical, immunohistochemical, and biomolecular screening may be useful for the identification of FAP among patients with a diagnosis of JNA. The Wnt pathway can be involved in the JNA pathogenesis either by somatic mutations of β-catenin or by germline APC mutations. As the VEGFR has an important impact on the pathogenesis of JNA, we suggest that a targeted therapy with monoclonal antibodies against VEGFR might lead to a specific chemoprevention and treatment of these tumors and their recurrences.
AB - Juvenile nasopharyngeal angiofibroma (JNA) is a rare, invasive, and locally destructive tumor of the nasopharynx. The Wnt pathway, angiogenetic and hormonal factors are involved in the pathophysiology of JNA; it can result in an extracolonic manifestation of familial adenomatous polyposis (FAP) or in a sporadic tumor. All patients who underwent resection of JNA between 1991 and 2006 at the University of Modena and Reggio Emilia were studied to identify immunohistochemical markers of associated FAP syndrome. Paraffin-embedded JNA samples were analyzed immunohistochemically for the expression of adenomatous polyposis coli (APC), β-catenin, E-cadherin, androgen receptor, and vascular endothelial growth factors receptor (VEGFR2). In one out of the 4 (25%) young patients affected by JNA the diagnosis of FAP syndrome linked to APC mutation was made. All of the sporadic and familial JNA tumors showed nuclear staining of β-catenin, whereas altered APC expression was seen only in FAP-associated JNA. All cases were stained with VEGFR2. A combined clinical, immunohistochemical, and biomolecular screening may be useful for the identification of FAP among patients with a diagnosis of JNA. The Wnt pathway can be involved in the JNA pathogenesis either by somatic mutations of β-catenin or by germline APC mutations. As the VEGFR has an important impact on the pathogenesis of JNA, we suggest that a targeted therapy with monoclonal antibodies against VEGFR might lead to a specific chemoprevention and treatment of these tumors and their recurrences.
KW - APC
KW - B-catenin
KW - E-cadherin
KW - Familial adenomatous polyposis
KW - Juvenile nasopharyngeal angiofibromas
KW - VEGFR
UR - http://www.scopus.com/inward/record.url?scp=46749083936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46749083936&partnerID=8YFLogxK
U2 - 10.1097/PAI.0b013e31806bee12
DO - 10.1097/PAI.0b013e31806bee12
M3 - Article
C2 - 18227724
AN - SCOPUS:46749083936
VL - 16
SP - 173
EP - 178
JO - Applied Immunohistochemistry
JF - Applied Immunohistochemistry
SN - 1541-2016
IS - 2
ER -